	US 7,476,658 B2
	Conjugate for treating prokaryotic infections
Klaus Braun, Sandhausen (Germany); Isabell Braun, Cölbe-Bürgein (Germany); Jürgen Debus, Heidelberg (Germany); Rudiger Pipkorn, Heidelberg (Germany); and Waldemar Waldeck, Laudenbach (Germany)
Assigned to Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts, (Germany)
Appl. No. 10/501,962 PCT Filed Jan. 17, 2003, PCT No. PCT/DE03/00124 § 371(c)(1), (2), (4) Date Oct. 04, 2004, PCT Pub. No. WO03/059392, PCT Pub. Date Jul. 24, 2003.
Claims priority of application No. 102 01 862 (DE), filed on Jan. 18, 2002.
Prior Publication US 2005/0222008 A1, Oct. 06, 2005
Int. Cl. A61K 31/70 (2006.01); C07H 21/04 (2006.01); C12N 5/00 (2006.01); C12Q 1/68 (2006.01)

U.S. Cl. 514—44 [536/24.1; 536/24.5; 435/6]

11 Claims

1. A conjugate suited for treating prokaryotic infections, comprising the following components:

(a) a phage-holin protein as transport peptide or protein adapted to penetrate the infectious prokaryote; and linked by a covalent bond thereto;

(b) a peptide nucleic acid (PNA) to be introduced into the prokaryote and directed against a DNA of a gene giving antibiotic resistance, wherein the peptide nucleic acid inhibits the transcription of the gene.